News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa
Saturday, May 20, 2023Today the US Food and Drug Administration approved Vyjuvek a herpessimplex virus type HSV vectorbased gene therapy for the treatment of wounds in patients months of age and older with dystrophic epidermolysis bullosa DEB with mutations in the colla...
RZNOMICS Inc. received FDA approval to initiate clinical development of trans-splicing ribozyme-based RNA editing technology in Glioblastoma Multiforme Patients
Saturday, May 20, 2023Rznomics Inc a South Korea based biopharmaceutical company specialized in the development of RNAbased gene therapeutics recently received Phase a IND approval from the US FDA on May th for its Glioblastoma Multiforme GBM treatment called RZ and thus...
The world's first such vaccine: The multivalent recombinant protein vaccine against XBB variant of COVID-19 from WestVac Biopharma
Saturday, May 20, 2023Bivalent Recombinant COVID Protein Vaccine Sf Cells and Trivalent Recombinant COVID Trimeric Protein Vaccine Sf Cells developed by WestVac BiopharmaWest China Medical Center Sichuan University against the most recent circulating XBB variants have rec...
Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease
Friday, May 19, 2023Bausch Lomb Corporation NYSETSX BLCO Bausch Lomb a leading global eye health company dedicated to helping people see better to live better and Novaliq GmbH a biopharmaceutical company focusing on first and bestin class ocular therapeutics today ann...
U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
Friday, May 19, 2023AbbVie NYSE ABBV today announced that the US Food and Drug Administration FDA has approved RINVOQ upadacitinib for the treatment of adults with moderately to severely active Crohns disease who have had an inadequate response or intolerance to one or...
GenScript Expands Peptide and Oligonucleotide Production Facility in China
Friday, May 19, 2023GenScript Biotech Corporation the worlds leading provider of lifescience research tools and services has expanded its primary manufacturing facility for oligonucleotide and peptide production at Zhenjiang Jiangsu China The expansion builds on GenScri...
Revvity Announces New License Agreement for Next-Generation Base Editing Technology
Friday, May 19, 2023Revvity Inc NYSE RVTY today announced a new license agreement with AstraZeneca LSESTONasdaq AZN for the technology underlying its Pinpoint base editing system a nextgeneration modular gene editing platform with a strong safety profile
Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction
Thursday, May 18, 2023Sania Therapeutics the Company focused on developing genetic medicines for neural circuit dysfunction launches today by unveiling its suite of proprietary patented platforms at the American Society of Gene Cell Therapy ASGCT conference
U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Thursday, May 18, 2023Takeda TSE NYSETAK today announced that the US Food and Drug Administration FDA has accepted Takedas Biologics License Application BLA for TAK an enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura cTTP an A...
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031
Thursday, May 18, 2023Antengene Corporation Limited Antengene SEHK HK a leading innovative commercialstage global biopharmaceutical company dedicated to discovering developing and commercializing firstinclass andor bestinclass therapeutics in hematology and oncology today...
